| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 11/11/2009 | EP2114937A1 Phenothiazin derivates, method for the production thereof and use thereof as pharmaceuticals |
| 11/11/2009 | EP2114924A2 Co-crystals and pharmaceutical compositions comprising the same |
| 11/11/2009 | EP2114922A1 Substituted oxindole derivative and its use as a vasopressin receptor modulator |
| 11/11/2009 | EP2114920A1 Substituted isoquinoline and isoquinolinone derivatives |
| 11/11/2009 | EP2114918A1 Process for solvent removal from omeprazole salts |
| 11/11/2009 | EP2114917A2 Pyrrole compounds |
| 11/11/2009 | EP2114913A1 Thiophene derivatives useful as ocular hypotensive agents |
| 11/11/2009 | EP2114904A1 Antifungal triazole derivatives, method for the preparation thereof and pharmaceutical composition containing same |
| 11/11/2009 | EP2114902A2 Hiv inhibiting 5,6-substituted pyrimidines |
| 11/11/2009 | EP2114901A1 Hiv inhibiting 6-substituted pyrimidines |
| 11/11/2009 | EP2114900A1 Thiopyrimidine-based compounds and uses thereof |
| 11/11/2009 | EP2114896A1 Radioprotector compounds and related methods |
| 11/11/2009 | EP2114894A1 Heterocyclyl-substituted-ehylamino-phenyl derivatives, their preparation and use as medicaments |
| 11/11/2009 | EP2114893A1 Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-ht7 receptor ligands |
| 11/11/2009 | EP2114892A1 Substituted pyrazoline compounds with acat inhibition activity, their preparation and use as medicaments |
| 11/11/2009 | EP2114888A1 Tricyclic compounds and their use as glucocorticoid receptor modulators |
| 11/11/2009 | EP2114881A1 Process for the purification of carvedilol or its salts thereof |
| 11/11/2009 | EP2114879A1 Ppar active compounds |
| 11/11/2009 | EP2114878A1 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands |
| 11/11/2009 | EP2114877A1 Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| 11/11/2009 | EP2114875A1 Substituted arylcylopentenes as therapeutic agents |
| 11/11/2009 | EP2114870A1 Synthetic ion channels |
| 11/11/2009 | EP2114867A1 Aminoamides as orexin antagonists |
| 11/11/2009 | EP2114862A1 Process for the preparation of o-desmethyl venlafaxine |
| 11/11/2009 | EP2114530A2 Treatment of faecal incontinence |
| 11/11/2009 | EP2114460A2 Methods and compositions for the disruption of biofilms |
| 11/11/2009 | EP2114442A1 Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| 11/11/2009 | EP2114424A1 Solid betalain compositions and methods |
| 11/11/2009 | EP2114423A1 Product containing inactivated probiotic for children or infants |
| 11/11/2009 | EP2114418A1 Stabilized picoplatin oral dosage form |
| 11/11/2009 | EP2114415A1 Methods and compounds for the targeted delivery of agents to bone for interaction therewith |
| 11/11/2009 | EP2114414A1 Synthetic lipophilic inositol glycans for treatment of cancer and glucose-metabolism disorders |
| 11/11/2009 | EP2114412A2 Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
| 11/11/2009 | EP2114411A2 Composition and method for protecting mitochondria |
| 11/11/2009 | EP2114410A2 N-amino tetrahydrothiazine derivatives, method of manufacture and use |
| 11/11/2009 | EP2114409A2 Composition and method for treating or preventing skeletal muscle fibrosis |
| 11/11/2009 | EP2114408A1 Substituted aminopyrimidines as cholecystokinin-1 receptor modulators |
| 11/11/2009 | EP2114407A1 Use of sodium blockers for an early therapy of obstructive lung diseases |
| 11/11/2009 | EP2114406A1 Thioxanthene derivates usefulto treat infectious diseases |
| 11/11/2009 | EP2114404A1 Pharmaceutical compound and composition |
| 11/11/2009 | EP2114400A2 Use of riluzole and derivatives thereof for producing new drugs |
| 11/11/2009 | EP2114399A2 R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma) |
| 11/11/2009 | EP2114398A1 Isosorbide mononitrate derivatives for the treatment of ocular hypertension |
| 11/11/2009 | EP2114397A2 Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof |
| 11/11/2009 | EP2114396A2 Methods for enhancing exercise performance |
| 11/11/2009 | EP2114395A2 Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof |
| 11/11/2009 | EP2114394A1 Platinum analogs with bis-nitrile-containing ligands |
| 11/11/2009 | EP2114390A2 Methods for treating podocyte-related disorders |
| 11/11/2009 | EP2114388A1 Inhibitors of akt activity |
| 11/11/2009 | EP2114387A2 Use of compositions containing at least one lignane and/or neolignane for modulating testosterone levels |
| 11/11/2009 | EP2114386A1 Pharmaceutical composition for treatment of diabetic complications |
| 11/11/2009 | EP2114385A2 Transdermal therapeutic system for administering water-soluble active ingredients |
| 11/11/2009 | EP2114381A1 An oral sustained-release triple layer tablet |
| 11/11/2009 | EP2114376A1 Amine polymer compositions |
| 11/11/2009 | EP2114372A1 Pharmaceutical carrier composition and pharmaceutical composition |
| 11/11/2009 | EP2114368A1 Pharmaceutical compositions comprising a bisphosphonate compound |
| 11/11/2009 | EP2114367A1 Olopatadine formulations for topical nasal administration |
| 11/11/2009 | EP2114166A1 Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors |
| 11/11/2009 | EP2114158A1 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| 11/11/2009 | EP2114157A1 Phosphoramidate alkylator prodrugs for the treatment of cancer |
| 11/11/2009 | EP2114156A1 Chemical compounds, pharmaceutical compositions and methods |
| 11/11/2009 | EP2114155A1 Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses |
| 11/11/2009 | EP2114153A2 Treatment and prevention of neurodegenerative diseases using gene therapy |
| 11/11/2009 | EP2114151A1 Isomers of inositol niacinate and uses thereof |
| 11/11/2009 | EP2114147A2 Reducing side effects of tramadol |
| 11/11/2009 | EP2114145A2 Phenylalkylcarboxylic acid delivery agents |
| 11/11/2009 | EP2114137A2 Stabilisation of biological cell markers |
| 11/11/2009 | EP2010005B1 Treatment of poultry for reducing the feed conversion rate or for reducing the incidence of ascites |
| 11/11/2009 | EP2007753B1 Heterocyclic gaba alpha subtype selective receptor modulators |
| 11/11/2009 | EP1973540B1 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| 11/11/2009 | EP1960401B1 Tricyclic amide derivatives useful for treating obesity |
| 11/11/2009 | EP1960396B1 Carbamate compounds as 5-ht4 receptor agonists |
| 11/11/2009 | EP1917246B1 Benzoquinazoline derivatives and their use in treating bone disorders |
| 11/11/2009 | EP1915379B1 Olanzapine analogs and methods of use thereof |
| 11/11/2009 | EP1884240B1 Pharmaceutical for prevention or treatment of bone metabolic disease |
| 11/11/2009 | EP1874745B1 New 3-phenylpropionic acid derivatives and their use as ppar- gamma receptor ligands |
| 11/11/2009 | EP1868599B1 Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors |
| 11/11/2009 | EP1863464B1 O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof |
| 11/11/2009 | EP1856065B1 1,2,4-triazine derivatives, preparation and use thereof in human therapy |
| 11/11/2009 | EP1841770B1 Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 11/11/2009 | EP1833816B1 Substituted piperidines as renin inhibitors |
| 11/11/2009 | EP1831189B1 Tetralin and indane derivatives and uses thereof |
| 11/11/2009 | EP1830849B1 Fast release dosage forms for antibiotics |
| 11/11/2009 | EP1818052B1 Use of formoterol in the prophylactic and/or therapeutic treatment of muscle wasting and/or cachectic syndrome which are associated with catabolic conditions of certain diseases, such as cancer, aids, infections, diabetes and others |
| 11/11/2009 | EP1778673B1 Novel hydantoin derivatives for the treatment of obstructive airway diseases |
| 11/11/2009 | EP1768669B1 Pharmaceutical compositions for the treatment of leishmaniasis |
| 11/11/2009 | EP1765360B1 Anti-viral uses of borinic acid complexes |
| 11/11/2009 | EP1761492B1 1-benzyl-4-¬(5,6-dimethoxy-1-indanone)-2-yl methyl piperidine oxalate (donepezil oxalate) and its polymorphs |
| 11/11/2009 | EP1742937B1 Pyrrolopyrimidine derivatives for treating proliferative diseases |
| 11/11/2009 | EP1742908B1 Non-nucleoside reverse transcriptase inhibitors |
| 11/11/2009 | EP1729808B1 Combination therapy with azd2171 and 5-fu and/or cpt-11 |
| 11/11/2009 | EP1729807B1 Combination therapy with azd-2171 |
| 11/11/2009 | EP1713823B1 Hcv ns-3 serine protease inhibitors |
| 11/11/2009 | EP1713543B1 Use of substituted 1,2,3 indolizine derivatives for treating diseases associated with a pathological angiogenesis |
| 11/11/2009 | EP1699440B1 Method for the production of an administration form which is secured against misuse |
| 11/11/2009 | EP1694331B1 Methods for suppressing an immune response or a treating a proliferating disorder |
| 11/11/2009 | EP1694291B1 Endoparasiticidal agents for topical application |
| 11/11/2009 | EP1669462B1 Method of preparing alpha-glycosylisoquercitrin, intermediate therefor and by-product |
| 11/11/2009 | EP1668002B1 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
| 11/11/2009 | EP1606255B1 Cyclic derivatives as modulators of chemokine receptor activity |